We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Prevails: ESAs OK for Chemotherapy-Induced Anemia
Amgen Prevails: ESAs OK for Chemotherapy-Induced Anemia
March 14, 2008
Amgen and Johnson & Johnson (J&J) dodged a bullet Thursday after the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 13–1 to recommend that erythropoiesis-stimulating agents (ESAs) continue to be marketed for chemotherapy-induced anemia.